NervGen Pharma Corp.

NervGen Pharma Corp. is a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The company's lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide designed to target the inhibitory CSPG-PTPσ pathway, licensed exclusively worldwide from Case Western Reserve University. NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency for SCI treatment. NervGen is preparing to initiate RESTORE, a Phase 3 registrational study of NVG-291 in approximately 150 adults with chronic cervical SCI, with site activation expected in September 2026. The company also holds exclusive worldwide rights to NVG-300, a next-generation candidate for neurotraumatic and neurologic conditions. NervGen has two wholly owned subsidiaries: NervGen US Inc. (Delaware) and NervGen Australia Pty Ltd. (Queensland). Common shares trade on the Nasdaq Capital Market under the symbol NGEN. The company is pre-revenue, with operations funded through equity offerings including a US$60 million underwritten public offering completed in May 2026. NervGen maintains a US$250 million shelf prospectus and a US$50 million ATM facility for future capital raises. Updated Aug 13, 2026